Global Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Region: COVID-19 Impact and Growth Opportunity
2021-05-30
22
207
Summary
Global preventive vaccines market will reach $80.47 billion by 2026, growing by 11.26% annually over 2020-2026 owing to increasing healthcare expenditure, new development of the vaccines, and rising need for preventive vaccines especially new COVID-19 vaccines.
Highlighted with 110 tables and 84 figures, this 207-page report ?Global Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Region: COVID-19 Impact and Growth Opportunity? is based on a holistic research of the entire global preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides estimate/forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
? Market Structure
? Growth Drivers
? Restraints and Challenges
? Emerging Product Trends & Market Opportunities
? Porter?s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Region.
Based on Vaccine Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
? Live/Attenuated Vaccines
? Inactivated Vaccines
? Subunit Vaccines
? Toxoid Vaccines
? Conjugate Vaccines
? Recombinant Vector Vaccines
? Other Vaccines
Based on Disease, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
? Vaccines for Pneumococcal Disease
? Vaccines for Poliovirus
? Vaccines for Hepatitis
? Vaccines for Influenza
? Vaccines for Measles, Mumps, and Rubella (MMR)
? Vaccines for Varicella
? Vaccines for Human Papilloma Virus
? Vaccines for COVID-19
? Vaccines for Other Diseases
Based on Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
? Intramuscular Route
? Subcutaneous Route
? Oral Route
? Intravenous Injection
? Other Administration Routes
Based on Patient, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
? Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
? Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases
Geographically, the following regions together with the listed national/local markets are fully investigated:
? APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
? Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
? North America (U.S., Canada, and Mexico)
? South America (Brazil, Colombia, Argentina, Rest of South America)
? MEA (Saudi Arabia, UAE, Egypt)
For each region and key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of all regional markets by country and split of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in global preventive vaccines market are assayed quantitatively and qualitatively through GMD?s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Region
Worldwide
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 23
2.1.2 Impact of COVID-19 on the Market 25
2.2 Major Growth Drivers 27
2.3 Market Restraints and Challenges 30
2.4 Emerging Opportunities and Market Trends 33
2.5 Porter?s Fiver Forces Analysis 37
3 Segmentation of Global Market by Vaccine Type 41
3.1 Market Overview by Vaccine Type 41
3.2 Live/Attenuated Vaccines 43
3.3 Inactivated Vaccines 44
3.4 Subunit Vaccines 45
3.5 Toxoid Vaccines 46
3.6 Conjugate Vaccines 47
3.7 Recombinant Vector Vaccines 48
3.8 Other Vaccines 49
4 Segmentation of Global Market by Disease 50
4.1 Market Overview by Disease 50
4.2 Vaccines for Pneumococcal Disease 52
4.3 Vaccines for Poliovirus 53
4.4 Vaccines for Hepatitis 54
4.5 Vaccines for Influenza 55
4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 56
4.7 Vaccines for Varicella 57
4.8 Vaccines for Human Papilloma Virus 58
4.9 Vaccines for COVID-19 59
4.10 Vaccines for Other Diseases 62
5 Segmentation of Global Market by Administration 63
5.1 Market Overview by Administration 63
5.2 Intramuscular Route 65
5.3 Subcutaneous Route 66
5.4 Oral Route 67
5.5 Intravenous Injection 68
5.6 Other Administration Routes 69
6 Segmentation of Global Market by Patient 70
6.1 Market Overview by Patient 70
6.2 Pediatric Vaccines 72
6.3 Adult Vaccines 74
7 Segmentation of Global Market by Region 76
7.1 Geographic Market Overview 2020-2026 76
7.2 North America Market 2020-2026 by Country 80
7.2.1 Overview of North America Market 80
7.2.2 U.S. 83
7.2.3 Canada 88
7.2.4 Mexico 91
7.3 European Market 2020-2026 by Country 94
7.3.1 Overview of European Market 94
7.3.2 UK 97
7.3.3 France 100
7.3.4 Germany 103
7.3.5 Spain 106
7.3.6 Italy 109
7.3.7 Russia 112
7.3.8 Rest of European Market 115
7.4 Asia-Pacific Market 2020-2026 by Country 117
7.4.1 Overview of Asia-Pacific Market 117
7.4.2 China 120
7.4.3 Japan 123
7.4.4 India 127
7.4.5 Australia 130
7.4.6 South Korea 133
7.4.7 Rest of APAC Region 136
7.5 South America Market 2020-2026 by Country 138
7.5.1 Argentina 141
7.5.2 Brazil 144
7.5.3 Colombia 147
7.5.4 Rest of South America Market 150
7.6 MEA Market 2020-2026 by Country 151
7.6.1 UAE 154
7.6.2 Saudi Arabia 157
7.6.3 Egypt 160
7.6.4 Other National Markets 163
8 Competitive Landscape 164
8.1 Overview of Key Vendors 164
8.2 New Product Launch, Partnership, Investment, and M&A 167
8.3 Company Profiles 168
AstraZeneca plc 168
Bavarian Nordic A/S 171
China National Biotec Group Company Ltd. 174
CSL Ltd. 176
Daiichi Sankyo Co. Ltd 178
Emergent BioSolutions Inc. 180
GlaxoSmithKline plc 182
Johnson & Johnson 186
Merck & Co. 188
Moderna Inc. 190
Novavax, Inc. 191
Pfizer Inc. 193
Sanofi SA 197
Takeda Pharmaceutical Co. Ltd. 199
9 Investing in Global Market: Risk Assessment and Management 201
9.1 Risk Evaluation of Global Market 201
9.2 Critical Success Factors (CSFs) 204
Related Reports and Products 207
Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2026 18
Figure 4. Global Preventive Vaccines Market, 2016-2026, $ mn 21
Figure 5. Development Stages of Preventive Vaccines 22
Figure 6. Impact of COVID-19 on Business 25
Figure 7. Primary Drivers and Impact Factors of Global Preventive Vaccines Market 27
Figure 8. Primary Restraints and Impact Factors of Global Preventive Vaccines Market 30
Figure 9. Investment Opportunity Analysis 34
Figure 10. Porter?s Fiver Forces Analysis of Global Preventive Vaccines Market 37
Figure 11. Breakdown of Global Preventive Vaccines Market by Vaccine Type, 2020-2026, % of Revenue 42
Figure 12. Contribution to Global 2021-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%) 42
Figure 13. Global Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn 43
Figure 14. Global Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn 44
Figure 15. Global Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn 45
Figure 16. Global Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn 46
Figure 17. Global Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn 47
Figure 18. Global Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn 48
Figure 19. Global Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn 49
Figure 20. Breakdown of Global Preventive Vaccines Market by Disease, 2020-2026, % of Revenue 51
Figure 21. Contribution to Global 2021-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%) 51
Figure 22. Global Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn 52
Figure 23. Global Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn 53
Figure 24. Global Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn 54
Figure 25. Global Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn 55
Figure 26. Global Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn 56
Figure 27. Global Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn 57
Figure 28. Global Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn 58
Figure 29. Global Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn 59
Figure 30. Global Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn 62
Figure 31. Breakdown of Global Preventive Vaccines Market by Administration, 2020-2026, % of Revenue 64
Figure 32. Contribution to Global 2021-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%) 64
Figure 33. Global Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn 65
Figure 34. Global Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn 66
Figure 35. Global Preventive Vaccines Market: Oral Route, 2016-2026, $ mn 67
Figure 36. Global Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn 68
Figure 37. Global Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn 69
Figure 38. Breakdown of Global Preventive Vaccines Market by Patient, 2020-2026, % of Revenue 70
Figure 39. Contribution to Global 2021-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%) 71
Figure 40. Global Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn 72
Figure 41. Global Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn 74
Figure 42. Global Market Snapshot by Region 76
Figure 43. Geographic Spread of Worldwide Preventive Vaccines Market, 2020-2026, % of Revenue 77
Figure 44. Contribution to Global 2021-2026 Cumulative Revenue by Region, Value ($ mn) and Share (%) 78
Figure 45. North American Preventive Vaccines Market, 2016-2026, $ mn 81
Figure 46. Breakdown of North America Preventive Vaccines Market by Country, 2020 and 2026, % of Revenue 81
Figure 47. Contribution to North America 2021-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 82
Figure 48. U.S. Preventive Vaccines Market, 2016-2026, $ mn 84
Figure 49. Canada Preventive Vaccines Market, 2016-2026, $ mn 88
Figure 50. Preventive Vaccines Market in Mexico, 2016-2026, $ mn 91
Figure 51. European Preventive Vaccines Market, 2016-2026, $ mn 95
Figure 52. Breakdown of European Preventive Vaccines Market by Country, 2020 and 2026, % of Revenue 95
Figure 53. Contribution to Europe 2021-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 96
Figure 54. Preventive Vaccines Market in UK, 2016-2026, $ mn 97
Figure 55. Preventive Vaccines Market in France, 2016-2026, $ mn 100
Figure 56. Preventive Vaccines Market in Germany, 2016-2026, $ mn 103
Figure 57. Preventive Vaccines Market in Spain, 2016-2026, $ mn 106
Figure 58. Preventive Vaccines Market in Italy, 2016-2026, $ mn 109
Figure 59. Preventive Vaccines Market in Russia, 2016-2026, $ mn 112
Figure 60. Preventive Vaccines Market in Rest of Europe, 2016-2026, $ mn 115
Figure 61. Asia-Pacific Preventive Vaccines Market, 2016-2026, $ mn 118
Figure 62. Breakdown of APAC Preventive Vaccines Market by Country, 2020 and 2026, % of Revenue 118
Figure 63. Contribution to APAC 2021-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 119
Figure 64. Preventive Vaccines Market in China, 2016-2026, $ mn 120
Figure 65. Preventive Vaccines Market in Japan, 2016-2026, $ mn 124
Figure 66. Preventive Vaccines Market in India, 2016-2026, $ mn 127
Figure 67. Preventive Vaccines Market in Australia, 2016-2026, $ mn 130
Figure 68. Preventive Vaccines Market in South Korea, 2016-2026, $ mn 133
Figure 69. Preventive Vaccines Market in Rest of APAC, 2016-2026, $ mn 136
Figure 70. South America Preventive Vaccines Market, 2016-2026, $ mn 139
Figure 71. Breakdown of South America Preventive Vaccines Market by Country, 2020 and 2026, % of Revenue 139
Figure 72. Contribution to South America 2021-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 140
Figure 73. Preventive Vaccines Market in Argentina, 2016-2026, $ mn 141
Figure 74. Preventive Vaccines Market in Brazil, 2016-2026, $ mn 144
Figure 75. Preventive Vaccines Market in Colombia, 2016-2026, $ mn 147
Figure 76. Preventive Vaccines Market in Rest of South America, 2016-2026, $ mn 150
Figure 77. Preventive Vaccines Market in Middle East and Africa (MEA), 2016-2026, $ mn 152
Figure 78. Breakdown of MEA Preventive Vaccines Market by Country, 2020 and 2026, % of Revenue 152
Figure 79. Contribution to MEA 2021-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 153
Figure 80. Preventive Vaccines Market in UAE, 2016-2026, $ mn 154
Figure 81. Preventive Vaccines Market in Saudi Arabia, 2016-2026, $ mn 157
Figure 82. Preventive Vaccines Market in Egypt, 2016-2026, $ mn 160
Figure 83. Growth Stage of Global Preventive Vaccines Industry over the Forecast Period 164
Figure 84. Top Products of AstraZeneca Based on Revenue from 2016 to 2019 (in million U.S. dollars) 169
